Albert David Past Earnings Performance

Past criteria checks 5/6

Albert David has been growing earnings at an average annual rate of 26.1%, while the Pharmaceuticals industry saw earnings growing at 14.9% annually. Revenues have been growing at an average rate of 2.5% per year. Albert David's return on equity is 18.9%, and it has net margins of 18.7%.

Key information

26.1%

Earnings growth rate

26.1%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate2.5%
Return on equity18.9%
Net Margin18.7%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown
Beta

How Albert David makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BSE:524075 Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 233,5486629090
30 Sep 233,4115818810
30 Jun 233,4035798860
31 Mar 233,4163628900
31 Dec 223,3453669260
30 Sep 223,3163409270
30 Jun 223,2562669360
31 Mar 223,1353539350
31 Dec 212,9593849110
30 Sep 212,8953659060
30 Jun 212,7483378280
31 Mar 212,4742218870
31 Dec 202,5071169420
30 Sep 202,6501079540
30 Jun 202,829889760
31 Mar 203,2081929940
31 Dec 193,2852991,0040
30 Sep 193,2592721,0150
30 Jun 193,1411981,0240
31 Mar 193,1691771,0130
31 Dec 183,1601791,0260
30 Sep 183,1362061,0010
30 Jun 183,2712879930
31 Mar 182,8741359710
31 Dec 172,976761,0550
30 Sep 172,799171,0650
30 Jun 172,78441,0590
31 Mar 172,9491711,0030
31 Dec 163,0081031,0400
30 Sep 163,130681,0290
30 Jun 163,165708400
31 Mar 163,226729870
31 Dec 153,229811,45639
30 Sep 153,2551391,44139
30 Jun 153,2361461,42539
31 Mar 153,2081379190
31 Dec 143,2871561,29643
30 Sep 143,1611361,26243
30 Jun 143,0321251,22143
31 Mar 142,8981261,19943
31 Dec 132,8251091,11825
30 Sep 132,727921,10025
30 Jun 132,696911,09525
31 Mar 132,641861,09125

Quality Earnings: 524075 has high quality earnings.

Growing Profit Margin: 524075's current net profit margins (18.7%) are higher than last year (10.9%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 524075's earnings have grown significantly by 26.1% per year over the past 5 years.

Accelerating Growth: 524075's earnings growth over the past year (80.9%) exceeds its 5-year average (26.1% per year).

Earnings vs Industry: 524075 earnings growth over the past year (80.9%) exceeded the Pharmaceuticals industry 23.8%.


Return on Equity

High ROE: 524075's Return on Equity (18.9%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.